Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080011
Chunk: 33

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 33
---
| Weighted-average discount rate for operating       
 leases                                             |     |             |      9.60 | % |     |              |      9.60 | % |

The following table reconciles the undiscounted future minimum lease payments under the non-cancelable operating lease with terms of more than one year to the total operating lease liabilities recognized on the Company’s balance sheet as of June 30, 2025:

Maturity of the Company’s lease liabilities as of June 30, 2025 is as follows:

| 2025 (remainder of year) |     | $ |   499,929 |   |
| 2026                     |     |   |   726,394 |   |
| Total lease payments     |     |   | 1,226,323 |   |
| Less: imputed interest   |     |   |   (73,705 | ) |
| Total lease liabilities  |     | $ | 1,152,618 |   |

NOTE 8 – STOCKHOLDERS’ DEFICIT

Successor Series A Convertible Preferred Stock

The Company designated 12,580 shares of its authorized preferred stock as the Series A Preferred Stock and the rights, preferences and privileges of the Series A Preferred Stock are summarized below.

Each share of Series A Preferred Stock has a stated value of $1,000
per share and, when issued, the Series A Preferred Stock was fully paid and non-assessable. The Series A Preferred Stock, ranks senior
to all other Company capital stock unless required holder votes are obtained to create a class of stock senior to Series A Preferred Stock.
The requisite holders of Series A Preferred Stock consented to the issuance of the Series C Preferred Stock and Series D Preferred Stock,
each as described below, which ranks senior to the Series A Preferred Stock and Series B Preferred Stock.

<div align='center'>15</div>

Dividend and Participation Rights:The holders of Series A Preferred Stock will be entitled to dividends, on an as-if converted basis, equal to and in the same form as dividends actually paid on shares of Common Stock, when and if actually paid. Series A Preferred Stockholders will be entitled to participate pro rata in any purchase rights extended to holders of Common Stock on an as-converted basis.

Conversion: Each holder of Series A Preferred Stock may convert at any time, all, or any part, of the outstanding Series A Preferred Stock into shares of the Common Stock at the initial “Conversion Price” of $20,